Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Double-response drug release MOFs@IBU nanofiber transdermal slow-release material as well as preparation method and application thereof

A nanofiber and sustained-release material technology, applied in the field of biomedical materials, can solve problems such as side effects and severe gastrointestinal problems, and achieve the effects of less side reactions, single product, and simple and easy-to-control reaction conditions.

Active Publication Date: 2021-04-20
SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, traditional ibuprofen oral preparations (such as tablets) will show more serious gastrointestinal side effects, and patients may also have adverse reactions such as palpitations, nausea, and dizziness.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Double-response drug release MOFs@IBU nanofiber transdermal slow-release material as well as preparation method and application thereof
  • Double-response drug release MOFs@IBU nanofiber transdermal slow-release material as well as preparation method and application thereof
  • Double-response drug release MOFs@IBU nanofiber transdermal slow-release material as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] A method for preparing a MOFs@IBU nanofiber transdermal sustained-release material with dual response drug release, comprising steps:

[0042] (1) Weigh 0.0505g ligand 4,4'-((4-(4H-1,2,4-triazol-4-yl)benzene)azodiacyl)dibenzoic acid, 0.074g hexahydrate Zinc nitrate and 0.0505g ibuprofen crude drug are dissolved in the mixed solvent of the pure water of 30ml and N, N-dimethylformamide (DMF) (pure water: N, N-dimethylformamide (DMF)= 1:1 (v / v)), and add diethanolamine (DEA) 150uL, mix well. After standing at room temperature for 24 hours, it was centrifuged and filtered, washed three times with DMF, and vacuum-dried at 63 °C to obtain a brown powder solid, that is, MOFs@IBU solid. The microscopic morphology of the obtained MOFs@IBU is a flower-shaped structure with a particle size of 90-400 nm.

[0043] (2) Weigh 0.7g of polyacrylonitrile (PAN, weight average molecular weight Mw=85000) and dissolve it in 10ml of N,N-dimethylformamide (DMF) to make a solution. Add 0.028...

Embodiment 2

[0046] A method for preparing a MOFs@IBU nanofiber transdermal sustained-release material with dual response drug release, comprising steps:

[0047] (1) Weigh 0.0505g ligand 4,4'-((4-(4H-1,2,4-triazol-4-yl)benzene)azodiacyl)dibenzoic acid and 0.0555g hexahydrate Zinc nitrate and 0.0505g ibuprofen crude drug are dissolved in the mixed solvent of the pure water of 30ml and N, N-dimethylformamide (DMF) (pure water: N, N-dimethylformamide (DMF)= 1:1 (v / v)), and add 140uL of diethanolamine (DEA), mix well. Stand at room temperature for 24 h, then centrifuge filter, wash with DMF three times, and vacuum-dry at 68 °C to obtain a brown powder solid, that is, MOFs@IBU solid. figure 1 For the SEM photographs of the resulting MOFs@IBU, from figure 1 It can be seen that the prepared MOFs@IBU has a flower-shaped structure with a size of about 90-300nm.

[0048] (2) Weigh 0.7g of polyacrylonitrile (PAN, weight average molecular weight Mw=150000) and dissolve it in 10ml of N,N-dimethylfo...

Embodiment 3

[0051] A method for preparing a MOFs@IBU nanofiber transdermal sustained-release material with dual response drug release, comprising steps:

[0052] (1) Weigh 0.0505g ligand 4,4'-((4-(4H-1,2,4-triazol-4-yl)benzene)azodiacyl)dibenzoic acid and 0.074g hexahydrate Zinc nitrate and 0.101g ibuprofen crude drug are dissolved in the mixed solvent of pure water and N,N-dimethylformamide (DMF) of 30ml (pure water: N,N-dimethylformamide (DMF)= 1:1 (v / v)), and add diethanolamine (DEA) 150uL, mix well. After standing at room temperature for 24 h, it was centrifuged and filtered, washed three times with DMF, and vacuum-dried at 70 °C to obtain a brown powder solid, that is, MOFs@IBU solid. figure 2 For the SEM photographs of the resulting MOFs@IBU, from figure 2 It can be seen that the prepared MOFs@IBU has a flower-shaped structure with a size of about 90-300nm.

[0053] (2) Weigh 0.7g of polyacrylonitrile (PAN, weight average molecular weight Mw=150000) and dissolve it in 10ml of N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides a double-response drug release MOFs@IBU nanofiber transdermal slow-release material as well as a preparation method and application thereof. The preparation method of the slow-release material comprises the following steps of dissolving ligand 4, 4'-((4-(4H-1, 2, 4-triazole-4-yl) benzene) azodiacyl) dibenzoic acid, zinc nitrate and ibuprofen in a mixed solvent of water and N, N-dimethylformamide, adding diethanolamine (DEA), uniformly mixing, standing at room temperature to react for 20-30 hours, centrifuging, washing and drying to obtain MOFs@IBU; dissolving polyacrylonitrile in N, N-dimethylformamide (DMF), adding MOFs@IBU, and uniformly mixing and dispersing to obtain a spinning solution; and then carrying out electrostatic spinning and drying. The nanofiber membrane obtained by the invention has pH and temperature dual-response drug release capability; and the preparation process is simple, the energy consumption is low, the structure of the drug loading system is easy to control, and the cost is relatively low.

Description

technical field [0001] The invention relates to a double-response drug release MOFs@IBU nanofiber transdermal slow-release material and its preparation method and application, belonging to the field of biomedical materials. Background technique [0002] MOFs materials (Metal-Organic Frameworks) are metal-organic framework compounds, which are a type of periodic network structure formed by self-assembly of inorganic metal centers (metal ions or metal clusters) and bridging organic ligands. porous material. It is different from both inorganic porous materials and general organic complexes. It has both the rigidity of inorganic materials and the flexibility of organic materials. It has a wide range of applications in the fields of gas separation, catalysis, sensing and drug loading. In the field of pharmacy, drug loading on MOFs materials has attracted much attention. MOFs materials loading drugs have the following advantages: first, MOFs materials have high porosity and large...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/70A61K31/192A61K47/32A61K47/69A61P29/00D04H1/43D04H1/728D04H3/007D04H3/02
Inventor 张平平程诗鸿王秋香张艳艳晁姝姝高照菊
Owner SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products